Nurix's stock price target has been lowered to $33 by Stifel due to rising expenses, which raises concerns about the company's financial health. This adjustment reflects the challenges Nurix faces in managing costs, potentially impacting investor confidence and market performance. Understanding these shifts is crucial for stakeholders as they navigate the evolving landscape of biotech investments.

Nurix's stock price target has been lowered to $12 by Leerink Partners, indicating a challenging outlook for the company. This adjustment reflects concerns about Nurix's performance and market position, which could impact investor confidence and the company's future growth prospects.